Business Trends– category –
-
Novel siRNA Drug SRN001 Targeting Amphiregulin via SAMiRNA Platform Demonstrates Favorable Safety in Phase 1 Trial
PMC (PubMed Central) International Overview A Phase 1 clinical trial for SRN001, a novel siRNA drug targeting amphiregulin delivered via the SAMiRNA platform, confirmed favorable safety and pharmacokinetic profiles. Notably, subjects exp... -
Lipid Nanoparticles (LNP) Overcome Nucleic Acid Respiratory and Gastrointestinal Mucosal Delivery Barriers, Opening New Avenues for Disease Treatment
MDPI Switzerland Overview Lipid nanoparticles (LNPs) are playing a crucial role in significantly enhancing the effectiveness of nucleic acid delivery to respiratory and gastrointestinal mucosa. LNPs have emerged as an effective strategy ... -
Nanomedicine Revolutionizes Epilepsy Treatment by Enhancing Blood-Brain Barrier Permeation, Targeting Neuroinflammation and Gut-Brain Axis, and Innovating Seizure Prediction and Suppression with Theranostics
PubMed (Journal of Controlled Release) International Overview Nanomedicine is being re-engineered as a novel strategy to overcome the limitations of conventional pharmacotherapy for intractable epilepsy, which is characterized by unpredi... -
Virus-Inspired Nanoparticles Revolutionize Drug and Gene Delivery, Overcoming Biological Barriers and Enhancing Cell-Specific Targeting for New Therapies
PMC International Overview Virus-inspired nanoparticles are emerging as a promising strategy for advanced drug and gene delivery. Viruses exhibit exceptional efficiency in overcoming biological barriers, targeting specific cells, and ind... -
Bioengineering Approaches in Nanomedicine Delivery for Myocardial Infarction Overcome Challenges in Targeting and Biocompatibility
American Heart Association Journals USA Overview Nanomedicine, utilizing synthetic nanoparticles and extracellular vesicles as primary delivery platforms, is emerging as a promising strategy for cardiovascular disease therapy, including ... -
Cell Membrane-Coated Nanoparticles Revolutionize Diabetic Wound Healing with Controlled Release and Extended Circulation for Chronic Wounds
PMC International Overview Cell membrane-coated nanoparticles (CMNPs) are emerging as an innovative and promising drug delivery platform for diabetic wound healing. CMNPs enable controlled and sustained drug release, significantly extend... -
Lineage Cell Therapeutics Continues Support for Roche/Genentech’s OpRegen Cell Therapy, AlloSCOPE™ Platform Enables Scalable Manufacturing
Business Wire USA Overview Lineage Cell Therapeutics reported Q2 2026 financial results and business updates, confirming continued support for its OpRegen cell therapy development collaboration with Roche and Genentech, including technic... -
CAR-T Cell Therapy Established for Specific B-Cell Lymphomas/Leukemias, but Product Differentiation and Individualized Adaptation Crucial
Regenex Asia Singapore Overview CAR-T cell therapy is firmly established for specific B-cell lymphomas and leukemias, but its clinical utility hinges on aligning individual products with appropriate disease settings due to varying target... -
Cell Therapy Clinical Success Hinges on Manufacturability: Limitations of Autologous Therapies Drive Interest in Allogeneic ‘Off-the-Shelf’ Platforms
Cell & Gene Unknown Overview Cell therapy scalability is a critical factor to consider from early development, as autologous therapies face challenges in manufacturing complexity, scheduling constraints, and inherent scalability limitati... -
EVERSANA Selected as Commercialization Partner for Innovacell Inc.’s Novel Cell Therapy ICEF15 for Urgent Fecal Incontinence in the United States
Outsourced Pharma USA Overview EVERSANA has been chosen by Tokyo-based biotechnology firm Innovacell Inc. as its exclusive commercialization partner in the United States. This partnership aims to advance regenerative medicine and cell th...
